Journal
SCIENCE
Volume 340, Issue 6132, Pages 626-630Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1236062
Keywords
-
Categories
Funding
- National Brain Tumor Society
- National Institutes of Health [1R01NS080944-01, U54CA143798]
- Leon Levy Foundation
- James S. McDonnell Foundation
- American Brain Tumor Association
- Lymphoma Research Foundation
- American Cancer Society
- American Society of Clinical Oncology
Ask authors/readers for more resources
The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy. One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers. Here, we examine the role of mutant IDH1 in fully transformed cells with endogenous IDH1 mutations. A selective R132H-IDH1 inhibitor (AGI-5198) identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). Under conditions of near-complete R-2HG inhibition, the mIDH1 inhibitor induced demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Blockade of mIDH1 impaired the growth of IDH1-mutant-but not IDH1-wild-type-glioma cells without appreciable changes in genome-wide DNA methylation. These data suggest that mIDH1 may promote glioma growth through mechanisms beyond its well-characterized epigenetic effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available